# US 11,026,905 B2 · STAT3 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,905 B2
- Document ID: US11026905B2
- Status: Granted
- Kind: B2
- Application number: 17/077,821
- Filed: 2020-10-22
- Published: 2021-02-11
- Granted: 2021-06-08
- Earliest claimed: 2018-04-19
- Assignees: Tvardi Therapeutics, Inc.; Baylor College of Medicine
- Applicants: Tvardi Therapeutics, Inc.; Baylor College of Medicine
- Inventors: Sofia De Achaval; David John Tweardy
- Web page: https://patentgrep.com/patent/US11026905B2

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds as STAT3 inhibitors are described. A pharmaceutical composition comprising the same, methods of making the same, and a method for treating or preventing conditions such as cancer, chronic inflammation, and fibrosis using the same, are described.

## Claims

### Claim 1

A pharmaceutical composition, comprising
(a) a compound of Formula III,
or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier or diluent.

### Claim 2 (depends on 1)

A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition according to claim 1, wherein the cancer is selected from the group consisting of: head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, prostate cancer, cervical cancer, brain cancer, pancreatic cancer, myelodysplastic syndrome, neuroblastoma, kidney cancer, and metastatic melanoma, wherein the compound of Formula III inhibits signal transducer and activator of transcription 3 (STAT3) thereby treating the cancer in the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cancer is selected from the group consisting of head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, and pancreatic cancer.

### Claim 4 (depends on 1)

A method of treating fibrosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition according to claim 1, wherein the compound of Formula III inhibits signal transducer and activator of transcription 3 (STAT3) thereby treating the fibrosis in the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the fibrosis is associated with a disease or disorder selected from the group consisting of: pulmonary fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis, retroperitoneal fibrosis, myelofibrosis, dermal fibrosis, non-alcoholic fatty liver disease, steatohepatitis, and systemic sclerosis.

### Claim 6 (depends on 4)

The method of claim 4, wherein the fibrosis is associated with pulmonary fibrosis, non-alcoholic fatty liver disease, steatohepatitis, or systemic sclerosis.